3 Promising Penny Stocks With At Least $200M Market Cap

Over the last 7 days, the market has remained flat, but it is up 16% over the past year with earnings forecast to grow by 15% annually. In light of these conditions, identifying stocks with strong financials and a clear growth trajectory can be beneficial. While "penny stocks" might seem like an outdated term, they still represent smaller or less-established companies that could offer significant value.

Top 10 Penny Stocks In The United States

Name Share Price Market Cap Financial Health Rating ATRenew (RERE) $4.68 $1.05B ★★★★★★ LexinFintech Holdings (LX) $2.14 $366.81M ★★★★★★ Tuya (TUYA) $2.34 $1.4B ★★★★★★ FinVolution Group (FINV) $4.89 $1.21B ★★★★★☆ Tuniu (TOUR) $0.7625 $89.34M ★★★★★★ Information Services Group (III) $3.11 $183.07M ★★★★★★ Golden Growers Cooperative (GGRO.U) $5.00 $77.45M ★★★★★★ Niagen Bioscience (NAGE) $4.52 $353.89M ★★★★★★ Cricut (CRCT) $3.90 $792.06M ★★★★★★ LifeVantage (LFVN) $4.20 $55.32M ★★★★★★

Click here to see the full list of 355 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

Anavex Life Sciences

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Anavex Life Sciences Corp. is a biopharmaceutical company with a market cap of $284.50 million.

Operations: Anavex Life Sciences Corp. currently does not report any revenue segments.

Market Cap: $284.5M

Anavex Life Sciences Corp., with a market cap of US$284.50 million, remains pre-revenue and debt-free, which is significant for a biopharmaceutical company focused on developing treatments for neurological conditions. Despite its unprofitability and volatile share price, Anavex has sufficient cash runway for over three years, providing financial stability as it advances its clinical development programs. Recent regulatory challenges include withdrawing an EU application for blarcamesine due to EMA feedback but continuing U.S. FDA engagements suggest ongoing commitment to Alzheimer's treatment development. The seasoned board and management team bolster confidence in navigating these complexities effectively.

Click to explore a detailed breakdown of our findings in Anavex Life Sciences' financial health report. Understand Anavex Life Sciences' earnings outlook by examining our growth report.AVXL Financial Position Analysis as at Apr 2026

Fossil Group

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Fossil Group, Inc. designs, develops, markets, and distributes consumer fashion accessories globally with a market cap of approximately $251.51 million.

Operations: The company's revenue is primarily derived from its operations in the Americas ($430.93 million), Europe ($333.25 million), and Asia ($238.65 million), with additional contributions from corporate activities ($1.58 million).

Story Continues

Market Cap: $251.51M

Fossil Group, Inc., with a market cap of US$251.51 million, faces challenges as it remains unprofitable and has seen increased losses over the past five years. Despite this, the company maintains sufficient short-term assets to cover both its short-term (US$301.8 million) and long-term liabilities (US$300.7 million). Recent earnings reports revealed a net loss of US$18.6 million for Q4 2025 on sales of US$280.5 million, down from the previous year’s figures. While management is relatively inexperienced with an average tenure of 1.2 years, Fossil's cash runway extends beyond three years if free cash flow reduction trends continue.

Get an in-depth perspective on Fossil Group's performance by reading our balance sheet health report here. Examine Fossil Group's earnings growth report to understand how analysts expect it to perform.FOSL Financial Position Analysis as at Apr 2026

Weave Communications

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Weave Communications, Inc. provides an AI-powered platform for patient communications, engagement, and payments tailored for small and medium-sized healthcare businesses, with a market cap of $363.36 million.

Operations: The company generates revenue through its Weave Platform, amounting to $239.02 million.

Market Cap: $363.36M

Weave Communications, Inc., with a market cap of US$363.36 million, is navigating the penny stock landscape by focusing on its AI-powered platform for healthcare communications and payments. Despite being unprofitable, Weave has reduced its losses over the past five years and maintains a strong cash position with sufficient runway exceeding three years due to positive free cash flow. Recent board changes aim to enhance value creation through strategic oversight, while partnerships like those with Minted Technology Advisors and Synchrony bolster its service offerings. Revenue growth is projected at 12.81% annually, although profitability remains elusive in the near term.

Unlock comprehensive insights into our analysis of Weave Communications stock in this financial health report. Learn about Weave Communications' future growth trajectory here.WEAV Financial Position Analysis as at Apr 2026

Key Takeaways

Reveal the 355 hidden gems among our US Penny Stocks screener with a single click here. Ready For A Different Approach? We've found 16 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AVXLFOSL and WEAV.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments